anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-17. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
=== Native chemical ligation === Native chemical ligation (NCL) is a convergent synthetic strategy based on the linear coupling of glycopeptide fragments. This technique makes use of the chemoselective reaction between a N-terminal cysteine residue on one peptide fragment with a thio-ester on the C-terminus of the other peptide fragment as illustrated below.
However, the exact age and provenance of CM 9401 remain uncertain due to a lack of detailed field documentation. In 2018, a paper describing tyrannosaurid teeth from the Two Medicine Formation noted a premaxillary tooth (YPM VPPU 023469) had a strong resemblance to the teeth of Sue to the exclusion of any Campanian tyrannosaurid. Additionally, the authors of this paper suggested that CM 9401 also comes from the Two Medicine Formation, as there were preservational similarities between its locality and the Willow Creek anticline, which is where the tooth was found. Notably, this would place both specimens in the Flag Butte Member of the Two Medicine Formation, which dates from 77 to 76.3 Ma, far older than any other Tyrannosaurus specimen, and directly contemporaneous with Daspletosaurus. In 2025, these specimens, with their old geologic age, were used as evidence by Charlie Scherer to suggest that the Tyrannosaurini did not evolve directly from Daspletosaurus.
There has been uncertainty about which biological target interactions mediate the psychoactive and other effects of ibogaine. Rodent drug discrimination studies with ibogaine have been employed to help elucidate these interactions. Ibogaine partially substitutes for the serotonergic psychedelics LSD and DOM and this can be blocked by the serotonin 5-HT2 receptor antagonist pizotifen. Similarly, LSD and DOM partially substitute for ibogaine and this can be blocked by the serotonin 5-HT2A receptor antagonist pirenperone. The serotonin releasing agent and potent serotonin 5-HT2 receptor agonist fenfluramine also partially substitutes for ibogaine. The preferential serotonin 5-HT2C receptor agonists MK-212 and mCPP partially substitute for ibogaine as well and this can be blocked by the serotonin 5-HT2 receptor antagonist metergoline. The preceding findings suggest that serotonin 5-HT2A and 5-HT2C receptor activation are involved in the subjective effects of ibogaine. Conversely, the serotonin 5-HT1A and 5-HT3 receptors do not appear to be involved. Although serotonin 5-HT2A receptor signaling appears to be involved in the effects of ibogaine, neither ibogaine nor its major active metabolite noribogaine appears to act as a direct serotonin 5-HT2A receptor agonist. In addition, in contrast to the findings in drug discrimination studies, ibogaine fails to produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
Sources: en.wikipedia.org
== Contributing factors and motivations == Corrective rape is a hate crime. A 2000 study suggested an atmosphere supportive of hate crimes against gay men and lesbians, reactions to hate crimes by the broader community, and responses by police and justice systems contribute to corrective rape. Often corrective rape is framed as something that can "fix" people who do not conform to gender norms or who are not heterosexual. ActionAid reports that survivors remember being told that they were being taught a lesson. Some perpetrators of the hate crime are impelled by a sense of misogyny and chauvinism. Personal experiences have included female victims being told they were "being shown what they were missing" while male victims have related gang rape accounts "where the objective was to make the experience of being sexually receptive so violent and frightening that the victim would fear potential homosexual experiences afterward". Some sources argue that many cases of corrective rape are caused by drawing moral conclusions from the nature–nurture debate. Despite the scientific community concluding that sexual orientation is the result of biology and environment, many people do not believe that homosexuality (or other forms of non-heterosexuality) has a genetic basis and instead believe it is only the result of one's environment. Because of this, some of these people believe sexual orientation can be changed or, as they see it, corrected.
primary structure The first order of complexity of structural organization exhibited by a polypeptide or protein molecule, or by a polynucleotide or nucleic acid molecule; i.e. the specific linear sequence of amino acid residues, or of nucleotides, without regard to their spatial arrangement or conformation or any higher-order structure (either secondary, tertiary, or quartenary) the molecule might assume. By convention, the primary structure of a polypeptide is reported from the amino (N)-terminus to the carboxyl (C)-terminus, and the primary structure of a nucleic acid is reported from the 5'-end to the 3'-end.
). This diffusivity leads to a break in the magnetic topology; magnetic field lines can "reconnect" when they collide. Usually, this term is small, and reconnections can be treated as similar to shocks; this process has been shown to be important in Earth-solar magnetic interactions. Extended Extended MHD describes a class of phenomena in plasmas that are higher-order than resistive MHD, but can adequately be treated with a single-fluid description. These include the effects of Hall physics, electron pressure gradients, finite Larmor radii in the particle gyromotion, and electron inertia. Two-fluid Two-fluid MHD describes plasmas that include a non-negligible Hall electric field. As a result, the electron and ion momenta must be treated separately. This description is more closely tied to Maxwell's equations because an evolution equation for the electric field exists. Hall In 1960, M. J. Lighthill criticized the applicability of ideal or resistive MHD theory for plasmas. This concerned the neglect of the "Hall current term" in Ohm's law, a frequent simplification made in magnetic fusion theory. Hall magnetohydrodynamics (HMHD) takes into account this electric-field description of magnetohydrodynamics, and Ohm's law takes the form:
A fifth vector is acknowledged to have occurred on 30 May 2007 FDA/USDA press conference, whereby U.S. manufacturers of livestock and shrimp/fish feed have acknowledged adding melamine to their products as a binder. The original Xuzhou Anying wheat gluten was "human grade," as opposed to "feed grade," meaning that it could have been used to make food for humans such as bread or pasta. At least one contaminated batch was used to make food for humans, but the FDA quarantined it before any was sold. The FDA also notified the Centers for Disease Control and Prevention to watch for new patients admitted to hospitals with renal failure. As of April 2007, there were no observed increases in human illnesses, and little human food tested as contaminated. Reports of widespread melamine adulteration in Chinese animal feed have raised the possibility of wider melamine contamination in the human food supply in China and abroad. Despite the widely reported ban on melamine use in vegetable proteins in China, at least some chemical manufacturers continue to report selling it for use in animal feed and in products for human consumption. Said Li Xiuping, a manager at Henan Xinxiang Huaxing Chemical in Henan Province: "Our chemical products are mostly used for additives, not for animal feed.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.